Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared neurostimulation therapy for the treatment of major depressive disorder and other mental health disorders. The company also offers Spravato, an esketamine nasal spray; and other treatment modalities for the treatment of depression and related psychiatric services. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.